
THE UNSTABLE HEMOGLOBINS:
SOME GENETIC ASPECTS
Wajcman H1,*, Galacteros F2 *Corresponding Author: Dr. Henri Wajcman, INSERM U 468 and Service de Biochimie, Hôpital Henri Mondor AP-HP, 51 Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France page: 3
|
UNSTABLE HEMOGLOBINS CARRIED BY THE α GENE
When the amount of α chains is insufficient to bind all the available β chains, the β chains in excess associate into homologous β4 tetramers named Hb H, which behave as a typically unstable Hb. In the case of unstable variants affecting the a chain, the situation is complex due to the presence of four a genes in normal individuals. An unstable a chain variant, when present in the heterozygous state, usually leads to a heterozygous α+- thal phenotype, which is similar to that resulting from nondeletional α-thal mutations. For example, Hb Bronte [α93 (FG5)Val→Gly (α2)] [35], which is the α chain equivalent of Hb Nottingham [β98(FG5)Val→Gly] [36], is expressed at α level of 6%. When present in the simple heterozygous state, such variants usually have very mild, or no apparent, hematological effects. Heterozygous carriers are usually identified by chance, when α Hb screening is performed in α population at-risk for the frequent hemoglobinopathies. They are suspected when α band that may correspond to an α chain variant, present at α very low level, is observed by isoelectrofocusing (IEF) or by cation exchange HPLC. When the substitutions are electrophoretically neutral they may pass unnoticed. Recently, several variants leading to borderline RBC parameters were identified by electrospray ionization mass spectrometry (ESI-MS). The example concerning Hb Esch, an α1 mutant [37], which amounted to less than 5% and resulted from the duplication of the 12 nucleotides corresponding to codons 65 through 68, is shown in Fig. 3.
When the carriers are homozygous, or compound heterozygous for another α chain abnormality, they may suffer from a severe hemolytic anemia, with the presence of α low percentage of Hb H. Having no deleterious consequence in the heterozygous state, they may be common in some populations, and thus found in several members of α family, explaining the possibility for homozygous cases. Hb Taybe [α1; 38 or 39 (Thr→0)] illustrates this situation: the variant was initially found in an Arabic family from Israel where the proband, who was homozygous, suffered from a severe hemolytic anemia with Hb H and some degree of dyserythropoiesis [38-40]. This variant was later found in several families belonging to this population, and also in other, completely different ethnic groups, as for example in China. Hb Sallanches [α104(G11)Cys→Tyr (α2)], was initially described in France in α homozygous patient with hemolytic anemia, while it is totally silent in the heterozygous state [41]. It was recently found to be a cause of nondeletional α-thal in Pakistan, leading also to Hb H when associated with another a chain abnormality [42,43]. The group of unstable a chain variants due to protein elongation at their C-terminal, such as Hbs Constant Spring or Paksé, are considered as a frequent and classic cause of nondeletional α-thal in Southeast Asia. Homozygous cases of Hb Constant Spring suffer from α chronic macrocytic hemolytic anemia with traces of Hb H. A few similar examples of unstable a chain variants with elongated chains were found in Greece, likely as the result of an intensive search for thalassemic mutations in this population. It may be important to know about the possibility of the presence of such unstable a chain variants, even in populations free of thalassemias, since today, with the large mobility of people, unexpected associated cases may occur. For example, a severe neonatal anemia was recently reported in twins born to an Irish-Scottish and Asian couple. Hemoglobin studies showed that the father was heterozygous for Hb Dartmouth [α66(E15)Leu→Pro (α2)] α silent unstable variant, while the mother was heterozygous for a Southeast Asian α0-thal [44]. In the past few years, the diagnosis of some unstable α chain variants was difficult when the structural abnormality resulted in α disturbed protein folding and in α defective subunit assembly. Paradoxical biosynthetic data with a β-thalassemic-like biosynthetic ratio after 1 hour of incubation, were then observed but not after short incubation times. Hb Questembert [α131(H14)Ser→Pro] [45,46] and Hb Ann Arbor [α80(F1)Leu→Arg] [47] illustrate this situation. These kinds of problems should easily be solved today by the use of ESI-MS, which would readily show that the abnormality is carried by an α chain, and by sequencing the α genes to find the abnormality. Due to the high frequency of the 3.7 kb deletion, the possibility exists for the mutation to be carried by the remaining recombinant α2α1 gene, which product normally amounts to 30-35% of the total α chains. Under these circumstances, the level of expression of an unstable a chain variant will become similar to that of a stable α1 mutation. To solve this problem, the recombinant α2α1 gene, which by PCR is usually amplified together with the α1 gene, should be isolated by electrophoresis before sequencing [48].
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|